Siponimod for Alzheimer's Disease (NCT06639282)

Overview

Siponimod (brand name: Mayzent) is a selective sphingosine-1-phosphate (S1P) receptor modulator being investigated for repurposing in Alzheimer's Disease at St. Joseph's Hospital. This trial (NCT06639282) evaluates the safety and efficacy of siponimod in patients with early to moderate AD, leveraging its immunomodulatory properties to target neuroinflammation—a key pathological driver of neurodegeneration[@josephs].

Siponimod is already approved by the FDA for treating relapsing forms of multiple sclerosis (MS), where it demonstrates robust efficacy in reducing disease activity and disability progression[@fda2019].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06639282 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | St. Joseph's Hospital |
| Intervention | Siponimod (oral) |
| Indication | Alzheimer's Disease |

Mechanism of Action

Sphingosine-1-Phosphate Receptor Modulation

Siponimod is a selective S1P receptor modulator that primarily targets:

S1P1 receptor: Predominantly expressed on lymphocytes

• Internalizes and degrades S1P1 receptors, preventing lymphocyte egress from lymphoid tissues
• Reduces circulating pro-inflammatory lymphocytes that can infiltrate the CNS
• Decreases CNS immune cell infiltration

S1P5 receptor: Expressed on astrocytes and oligodendrocytes

• Modulates glial cell function
• Promotes oligodendrocyte survival and myelination
• May support neuronal protection

Key Molecular Mechanisms

...

Overview

Siponimod (brand name: Mayzent) is a selective sphingosine-1-phosphate (S1P) receptor modulator being investigated for repurposing in Alzheimer's Disease at St. Joseph's Hospital. This trial (NCT06639282) evaluates the safety and efficacy of siponimod in patients with early to moderate AD, leveraging its immunomodulatory properties to target neuroinflammation—a key pathological driver of neurodegeneration[@josephs].

Siponimod is already approved by the FDA for treating relapsing forms of multiple sclerosis (MS), where it demonstrates robust efficacy in reducing disease activity and disability progression[@fda2019].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06639282 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | St. Joseph's Hospital |
| Intervention | Siponimod (oral) |
| Indication | Alzheimer's Disease |

Mechanism of Action

Sphingosine-1-Phosphate Receptor Modulation

Siponimod is a selective S1P receptor modulator that primarily targets:

S1P1 receptor: Predominantly expressed on lymphocytes

• Internalizes and degrades S1P1 receptors, preventing lymphocyte egress from lymphoid tissues
• Reduces circulating pro-inflammatory lymphocytes that can infiltrate the CNS
• Decreases CNS immune cell infiltration

S1P5 receptor: Expressed on astrocytes and oligodendrocytes

• Modulates glial cell function
• Promotes oligodendrocyte survival and myelination
• May support neuronal protection

Key Molecular Mechanisms

Neuroprotective Effects

Beyond immune modulation, siponimod may provide direct neuroprotection through:

Astrocyte modulation: S1P5 receptor signaling influences astrocyte reactivity and function

Oligodendrocyte support: Promotes survival and function of myelin-producing cells

Neurotrophic effects: S1P signaling can support neuronal survival pathways

Blood-brain barrier integrity: May improve BBB function and reduce leakiness

Rationale for Alzheimer's Disease

Neuroinflammation in AD

Alzheimer's Disease is characterized by:

• Amyloid-beta (Aβ) plaques: Accumulation of misfolded Aβ peptides
• Neurofibrillary tangles: Hyperphosphorylated tau protein aggregates
• Neuroinflammation: Chronic activation of microglia and astrocytes
• Synaptic dysfunction: Loss of neuronal connections

Neuroinflammation is now recognized as both a consequence and driver of AD pathology. Activated microglia release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that:

• Exacerbate amyloid deposition
• Promote tau pathology
• Accelerate synaptic loss
• Contribute to cognitive decline

Why S1P Modulation?

The S1P pathway is implicated in AD through multiple mechanisms:

Microglial activation: S1P receptors regulate microglial phenotype and function

Astrocyte reactivity: S1P signaling influences astrocyte-mediated neuroinflammation

Amyloid processing: S1P modulators may influence amyloid precursor protein (APP) processing

Tau pathology: S1P signaling can affect tau phosphorylation and aggregation

Siponimod's dual action on S1P1 and S1P5 receptors makes it a promising candidate for:

• Reducing peripheral immune cell CNS infiltration
• Modulating resident glial cell reactivity
• Supporting myelin integrity (relevant given oligodendrocyte involvement in AD)

Study Design

Trial Structure

Based on the Phase 2 trial design typical for AD drug repurposing studies:

| Phase | Duration | Arms |
|-------|----------|------|
| Screening | 4-6 weeks | N/A |
| Treatment | 52 weeks | Siponimod vs. Placebo |
| Follow-up | 12 weeks | Safety monitoring |

Primary Endpoints

• Cognitive: Change from baseline in ADAS-Cog13 or MMSE
• Safety: Adverse events, serious adverse events
• Biomarker: CSF or plasma neuroinflammation markers

Secondary Endpoints

• Brain imaging (MRI) for hippocampal volume
• CSF biomarkers (Aβ, tau, p-tau)
• Functional outcomes (ADCS-ADL, CDR)
• Pharmacokinetic assessments

Expected Outcomes

Hypothesized Benefits

If successful, siponimod could provide:

Cognitive stabilization: Reduced rate of cognitive decline

Neuroinflammation reduction: Lower CSF/Plasma inflammatory markers

Brain volume preservation: Reduced hippocampal atrophy

Disease modification: Evidence of slowed disease progression

Comparison with Other Approaches

| Approach | Target | Status |
|----------|--------|--------|
| Siponimod | S1P receptors (neuroinflammation) | Phase 2 |
| Aducanumab | Amyloid plaques | Approved |
| Lecanemab | Amyloid plaques | Approved |
| Donanemab | Amyloid plaques | Approved |
| Anti-inflammatory approaches | COX, IL-1 | Mixed results |

Siponimod represents a novel mechanism targeting neuroinflammation directly rather than amyloid removal.

Sphingolipid Metabolism

Siponimod interacts with the broader sphingolipid pathway:

• Sphingosine-1-phosphate (S1P): Bioactive lipid signaling molecule
• Sphingosine kinase (SPHK): Enzyme that produces S1P
• S1P receptors: G-protein coupled receptors (S1P1-S1P5)

Neuroinflammation Pathways

• Microglia Activation
• Astrocyte Reactivity
• Cytokine Signaling
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• Clinical Trials in AD
• Neuroinflammation Mechanisms
• Drug Repurposing for Neurodegeneration
• Sphingolipid Signaling
• Bristol Myers Squibb

External Links

• [ClinicalTrials.gov - NCT06639282](https://clinicaltrials.gov/study/NCT06639282)
• [Mayzent (Siponimod) - BMS](https://www.mayzent.com/)
• [S1P Receptor Overview - Nature](https://www.nature.com/articles/nrm3374)

References

Unknown, St. Joseph's Hospital. Siponimod for Alzheimer's Disease. ClinicalTrials.gov NCT06639282 (n.d.)

Unknown, FDA. Mayzent (siponimod) prescribing information (2019)

[Kappos L, et al, Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018)](https://pubmed.ncbi.nlm.nih.gov/29519765/)

[Choi JW, et al, FTY720 (fingolimod) is a sphingosine 1-phosphate receptor antagonist that suppresses experimental autoimmune encephalomyelitis (2005)](https://pubmed.ncbi.nlm.nih.gov/15824544/)

[van Doorn R, et al, Sphingosine 1-phosphate receptor 1 and 5 in the central nervous system (2010)](https://pubmed.ncbi.nlm.nih.gov/20553957/)

[imov J, et al, Role of sphingosine-1-phosphate signaling in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32731040/)

[Domeniconi G, et al, S1P receptor modulators in multiple sclerosis: a review of emerging data (2020)](https://pubmed.ncbi.nlm.nih.gov/31916055/)